Cargando…

Epitope Mapping: The First Step in Developing Epitope-Based Vaccines

Antibodies are an effective line of defense in preventing infectious diseases. Highly potent neutralizing antibodies can intercept a virus before it attaches to its target cell and, thus, inactivate it. This ability is based on the antibodies’ specific recognition of epitopes, the sites of the antig...

Descripción completa

Detalles Bibliográficos
Autores principales: Gershoni, Jonathan M., Roitburd-Berman, Anna, Siman-Tov, Dror D., Freund, Natalia Tarnovitski, Weiss, Yael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7100438/
https://www.ncbi.nlm.nih.gov/pubmed/17516710
http://dx.doi.org/10.2165/00063030-200721030-00002
_version_ 1783511441349804032
author Gershoni, Jonathan M.
Roitburd-Berman, Anna
Siman-Tov, Dror D.
Freund, Natalia Tarnovitski
Weiss, Yael
author_facet Gershoni, Jonathan M.
Roitburd-Berman, Anna
Siman-Tov, Dror D.
Freund, Natalia Tarnovitski
Weiss, Yael
author_sort Gershoni, Jonathan M.
collection PubMed
description Antibodies are an effective line of defense in preventing infectious diseases. Highly potent neutralizing antibodies can intercept a virus before it attaches to its target cell and, thus, inactivate it. This ability is based on the antibodies’ specific recognition of epitopes, the sites of the antigen to which antibodies bind. Thus, understanding the antibody/epitope interaction provides a basis for the rational design of preventive vaccines. It is assumed that immunization with the precise epitope, corresponding to an effective neutralizing antibody, would elicit the generation of similarly potent antibodies in the vaccinee. Such a vaccine would be a ‘B-cell epitope-based vaccine’, the implementation of which requires the ability to backtrack from a desired antibody to its corresponding epitope. In this article we discuss a range of methods that enable epitope discovery based on a specific antibody. Such a reversed immunological approach is the first step in the rational design of an epitope-based vaccine. Undoubtedly, the gold standard for epitope definition is x-ray analyses of crystals of antigen: antibody complexes. This method provides atomic resolution of the epitope; however, it is not readily applicable to many antigens and antibodies, and requires a very high degree of sophistication and expertise. Most other methods rely on the ability to monitor the binding of the antibody to antigen fragments or mutated variations. In mutagenesis of the antigen, loss of binding due to point modification of an amino acid residue is often considered an indication of an epitope component. In addition, computational combinatorial methods for epitope mapping are also useful. These methods rely on the ability of the antibody of interest to affinity isolate specific short peptides from combinatorial phage display peptide libraries. The peptides are then regarded as leads for the definition of the epitope corresponding to the antibody used to screen the peptide library. For epitope mapping, computational algorithms have been developed, such as Mapitope, which has recently been found to be effective in mapping conformational discontinuous epitopes. The pros and cons of various approaches towards epitope mapping are also discussed.
format Online
Article
Text
id pubmed-7100438
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-71004382020-03-27 Epitope Mapping: The First Step in Developing Epitope-Based Vaccines Gershoni, Jonathan M. Roitburd-Berman, Anna Siman-Tov, Dror D. Freund, Natalia Tarnovitski Weiss, Yael BioDrugs Drug Development Antibodies are an effective line of defense in preventing infectious diseases. Highly potent neutralizing antibodies can intercept a virus before it attaches to its target cell and, thus, inactivate it. This ability is based on the antibodies’ specific recognition of epitopes, the sites of the antigen to which antibodies bind. Thus, understanding the antibody/epitope interaction provides a basis for the rational design of preventive vaccines. It is assumed that immunization with the precise epitope, corresponding to an effective neutralizing antibody, would elicit the generation of similarly potent antibodies in the vaccinee. Such a vaccine would be a ‘B-cell epitope-based vaccine’, the implementation of which requires the ability to backtrack from a desired antibody to its corresponding epitope. In this article we discuss a range of methods that enable epitope discovery based on a specific antibody. Such a reversed immunological approach is the first step in the rational design of an epitope-based vaccine. Undoubtedly, the gold standard for epitope definition is x-ray analyses of crystals of antigen: antibody complexes. This method provides atomic resolution of the epitope; however, it is not readily applicable to many antigens and antibodies, and requires a very high degree of sophistication and expertise. Most other methods rely on the ability to monitor the binding of the antibody to antigen fragments or mutated variations. In mutagenesis of the antigen, loss of binding due to point modification of an amino acid residue is often considered an indication of an epitope component. In addition, computational combinatorial methods for epitope mapping are also useful. These methods rely on the ability of the antibody of interest to affinity isolate specific short peptides from combinatorial phage display peptide libraries. The peptides are then regarded as leads for the definition of the epitope corresponding to the antibody used to screen the peptide library. For epitope mapping, computational algorithms have been developed, such as Mapitope, which has recently been found to be effective in mapping conformational discontinuous epitopes. The pros and cons of various approaches towards epitope mapping are also discussed. Springer International Publishing 2012-08-15 2007 /pmc/articles/PMC7100438/ /pubmed/17516710 http://dx.doi.org/10.2165/00063030-200721030-00002 Text en © Adis Data Information BV 2007 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Drug Development
Gershoni, Jonathan M.
Roitburd-Berman, Anna
Siman-Tov, Dror D.
Freund, Natalia Tarnovitski
Weiss, Yael
Epitope Mapping: The First Step in Developing Epitope-Based Vaccines
title Epitope Mapping: The First Step in Developing Epitope-Based Vaccines
title_full Epitope Mapping: The First Step in Developing Epitope-Based Vaccines
title_fullStr Epitope Mapping: The First Step in Developing Epitope-Based Vaccines
title_full_unstemmed Epitope Mapping: The First Step in Developing Epitope-Based Vaccines
title_short Epitope Mapping: The First Step in Developing Epitope-Based Vaccines
title_sort epitope mapping: the first step in developing epitope-based vaccines
topic Drug Development
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7100438/
https://www.ncbi.nlm.nih.gov/pubmed/17516710
http://dx.doi.org/10.2165/00063030-200721030-00002
work_keys_str_mv AT gershonijonathanm epitopemappingthefirststepindevelopingepitopebasedvaccines
AT roitburdbermananna epitopemappingthefirststepindevelopingepitopebasedvaccines
AT simantovdrord epitopemappingthefirststepindevelopingepitopebasedvaccines
AT freundnataliatarnovitski epitopemappingthefirststepindevelopingepitopebasedvaccines
AT weissyael epitopemappingthefirststepindevelopingepitopebasedvaccines